Eddie Pan

Eddie Pan

Expertise: Institutional Investments, Insider Activity, Disruptive Innovations

Education: BBA, Finance, James Madison University

About Eddie:
Eddie Pan specializes in institutional investments and insider activity. He has been enamored with hedge funds since he began investing and regularly collaborates with industry executives to craft editorial pieces. Tracking the investments of institutional investors and insiders can provide a vast array of knowledge that is scarcely covered.

After receiving his BBA in Finance from James Madison University, Eddie began his career at Accenture as an analyst. Today, he writes for InvestorPlace’s Today’s Market team, which centers on the latest news involving popular stocks.

Eddie got his start in the financial media world by publishing articles on top-performing hedge funds and their investment strategies on Substack. He still publishes pieces on his Substack today.

Common Stocks and Uncommon Profits by Philip A. Fisher is Eddie’s favorite investment book. Fisher’s 15 Points have heavily influenced his investment strategy.

Recent Articles

Needham Just Raised Its Price Target on Rivian (RIVN) Stock

RIVN stock received several price target and rating adjustments after Rivian held its 2024 Investor Day event.

FFIE Stock: Faraday Future Just Received Conditional Approval for Continued Nasdaq Trading

FFIE stock is trading lower after the Nasdaq Hearing Panel allowed the company to continue trading on two conditions.

FFIE Stock Alert: Faraday Future Hosts Strategy Meeting With UAE Firm

FFIE stock is in focus after the company hosted a meeting with Master Investment Group and its CEO, Sheikh Abdullah Al Qassimi.

Nvidia Insiders Have Sold $852 Million Worth of NVDA Stock This Year

Nvidia insiders are approaching $1 billion of insider sales this year, although the sales aren't what they appear on the surface level.

Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report

HIMS stock is trading lower after Hunterbrook Media published a short report on the company, taking issue with its compounded GLP-1 drug.